NYSE:TDOC
Teladoc Health, Inc.
Teladoc Health, Inc.'s revenue fell 1.5% in fiscal 2025 to $2.5B while operating margin rose to −10.4%. Free cash flow was $285.5M, 11.3% of revenue, and the diluted share count rose 3.3%.Summary generated from Teladoc Health, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.5B
Revenue growth−1.5%
Revenue, 5-yr CAGR+18.3%
Gross marginn/a
Operating margin−10.4%
Net margin−7.9%
ROICn/a
Return on equity−13.9%
Debt / equityn/a
Free cash flow$285.5M
FCF margin11.3%
Share count change+3.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2,033 | 2,407 | 2,602 | 2,570 | 2,530 |
| Operating income | −266 | −13,653 | −249 | −1,021 | −263 |
| Net income | −429 | −13,660 | −220 | −1,001 | −200 |
| Free cash flow | 185 | 173 | 339 | 283 | 285 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 8-KDirector or officer change
Sep 25, 2026 - 4Insider transaction report
Sep 14, 2026 - 8-KDirector or officer change
Aug 31, 2026 - 8-KDirector or officer change
Aug 13, 2026 - 8-KDirector or officer change
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026